+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Heparin Market 2020-2024 - Product Image

Global Heparin Market 2020-2024

  • ID: 5004482
  • Report
  • January 2020
  • Region: Global
  • 166 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Baxter International Inc.
  • Eisai Co. Ltd.
  • Fresenius SE & Co. KGaA
  • Hikma Pharmaceuticals Plc
  • Mylan NV
  • Pfizer Inc.
  • MORE
Global Heparin Market 2020-2024.

The publisher has been monitoring the global heparin market and it is poised to grow by USD 941.2 mn during 2020-2024, progressing at a CAGR of 3% during the forecast period. The report on the global heparin market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of chronic conditions. In addition, development of drugs to remove heparin after surgery is anticipated to boost the growth of the global heparin market as well.

Market Segmentation

The global heparin market is segmented as below:

Product:
  • Low Molecular Weight Heparin
  • Others
Route Of Administration :
  • Subcutaneous Injection
  • Intravenous/infusion
Geographic Segmentation:
  • Asia
  • Europe
  • North America
  • ROW
Key Trends for global heparin market growth

This study identifies development of drugs to remove heparin after surgery as the prime reasons driving the global heparin market growth during the next few years.

Prominent vendors in global heparin market

The publisher a detailed analysis of around 25 vendors operating in the global heparin market , including some of the vendors such as Aspen Pharmacare Holdings Ltd., Baxter International Inc., Eisai Co. Ltd., Fresenius SE & Co. KGaA, Hikma Pharmaceuticals Plc, Laboratorios Farmaceuticos Rovi SA, Mylan NV, Nanjing King-Friend Biochemical Pharmaceutical Co. Ltd., Pfizer Inc. and Sanofi. .

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Baxter International Inc.
  • Eisai Co. Ltd.
  • Fresenius SE & Co. KGaA
  • Hikma Pharmaceuticals Plc
  • Mylan NV
  • Pfizer Inc.
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • 2. 2 Preface
  • 2. 3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Parent market
  • Market characteristics
  • Market segmentation analysis
  • Value chain analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2019
  • Market size and forecast 2019-2024
  • Market outlook
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
  • Market segmentation by product
  • Comparison by product
  • Low-molecular-weight heparin - Market size and forecast 2019-2024
  • Others - Market size and forecast 2019-2024
  • Market opportunity by product
PART 07: MARKET SEGMENTATION BY ROUTE OF ADMINISTRATION
  • Market segmentation by route of administration
  • Comparison by route of administration
  • Subcutaneous injection - Market size and forecast 2019-2024
  • Intravenous/infusion - Market size and forecast 2019-2024
  • Market opportunity by route of administration
PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • Europe - Market size and forecast 2019-2024
  • North America - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity
PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 12: MARKET TRENDS
  • Increasing R&D activities and new therapeutic applications of heparin
  • Advent of biosimilar low-molecular-weight heparin
  • Development of drugs to remove heparin after surgery
PART 13: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 14: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Aspen Pharmacare Holdings Ltd.
  • Baxter International Inc.
  • Eisai Co. Ltd.
  • Fresenius SE & Co. KGaA
  • Hikma Pharmaceuticals Plc
  • Laboratorios Farmaceuticos Rovi SA
  • Mylan NV
  • Nanjing King-Friend Biochemical Pharmaceutical Co. Ltd.
  • Pfizer Inc.
  • Sanofi
PART 15: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
List of Exhibits
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Product overview
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2019
Exhibit 08: Global market: Size and forecast 2019-2024 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2020-2024 (%)
Exhibit 10: Five forces analysis 2019
Exhibit 11: Five forces analysis 2024
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2019
Exhibit 18: Product - Market share 2019-2024 (%)
Exhibit 19: Comparison of product
Exhibit 20: Low-molecular-weight heparin - Market size and forecast 2019-2024 ($ millions)
Exhibit 21: Low-molecular-weight heparin - Year-over-year growth 2020-2024 (%)
Exhibit 22: Others - Market size and forecast 2019-2024 ($ millions)
Exhibit 23: Others - Year-over-year growth 2020-2024 (%)
Exhibit 24: Market opportunity by product
Exhibit 25: Route of administration - Market share 2019-2024 (%)
Exhibit 26: Comparison by route of administration
Exhibit 27: Subcutaneous injection - Market size and forecast 2019-2024 ($ millions)
Exhibit 28: Subcutaneous injection - Year-over-year growth 2020-2024 (%)
Exhibit 29: Intravenous/infusion - Market size and forecast 2019-2024 ($ millions)
Exhibit 30: Intravenous/infusion - Year-over-year growth 2020-2024 (%)
Exhibit 31: Market opportunity by route of administration
Exhibit 32: Customer landscape
Exhibit 33: Market share by geography 2019-2024 (%)
Exhibit 34: Geographic comparison
Exhibit 35: Europe - Market size and forecast 2019-2024 ($ millions)
Exhibit 36: Europe - Year-over-year growth 2020-2024 (%)
Exhibit 37: North America - Market size and forecast 2019-2024 ($ millions)
Exhibit 38: North America - Year-over-year growth 2020-2024 (%)
Exhibit 39: Asia - Market size and forecast 2019-2024 ($ millions)
Exhibit 40: Asia - Year-over-year growth 2020-2024 (%)
Exhibit 41: ROW - Market size and forecast 2019-2024 ($ millions)
Exhibit 42: ROW - Year-over-year growth 2020-2024 (%)
Exhibit 43: Key leading countries
Exhibit 44: Market opportunity
Exhibit 45: Decision framework
Exhibit 46: Impact of drivers and challenges
Exhibit 47: Vendor landscape
Exhibit 48: Landscape disruption
Exhibit 49: Vendors covered
Exhibit 50: Vendor classification
Exhibit 51: Market positioning of vendors
Exhibit 52: Aspen Pharmacare Holdings Ltd. - Vendor overview
Exhibit 53: Aspen Pharmacare Holdings Ltd. - Business segments
Exhibit 54: Aspen Pharmacare Holdings Ltd. - Organizational developments
Exhibit 55: Aspen Pharmacare Holdings Ltd. - Geographic focus
Exhibit 56: Aspen Pharmacare Holdings Ltd. - Segment focus
Exhibit 57: Aspen Pharmacare Holdings Ltd. - Key offerings
Exhibit 58: Aspen Pharmacare Holdings Ltd. - Key customers
Exhibit 59: Baxter International Inc. - Vendor overview
Exhibit 60: Baxter International Inc. - Business segments
Exhibit 61: Baxter International Inc. - Organizational developments
Exhibit 62: Baxter International Inc. - Geographic focus
Exhibit 63: Baxter International Inc. - Segment focus
Exhibit 64: Baxter International Inc. - Key offerings
Exhibit 65: Baxter International Inc. - Key customers
Exhibit 66: Eisai Co. Ltd. - Vendor overview
Exhibit 67: Eisai Co. Ltd. - Business segments
Exhibit 68: Eisai Co. Ltd. - Organizational developments
Exhibit 69: Eisai Co. Ltd. - Geographic focus
Exhibit 70: Eisai Co. Ltd. - Segment focus
Exhibit 71: Eisai Co. Ltd. - Key offerings
Exhibit 72: Eisai Co. Ltd. - Key customers
Exhibit 73: Fresenius SE & Co. KGaA - Vendor overview
Exhibit 74: Fresenius SE & Co. KGaA - Business segments
Exhibit 75: Fresenius SE & Co. KGaA - Organizational developments
Exhibit 76: Fresenius SE & Co. KGaA - Geographic focus
Exhibit 77: Fresenius SE & Co. KGaA - Segment focus
Exhibit 78: Fresenius SE & Co. KGaA - Key offerings
Exhibit 79: Fresenius SE & Co. KGaA - Key customers
Exhibit 80: Hikma Pharmaceuticals Plc - Vendor overview
Exhibit 81: Hikma Pharmaceuticals Plc - Business segments
Exhibit 82: Hikma Pharmaceuticals Plc - Organizational developments
Exhibit 83: Hikma Pharmaceuticals Plc - Geographic focus
Exhibit 84: Hikma Pharmaceuticals Plc - Segment focus
Exhibit 85: Hikma Pharmaceuticals Plc - Key offerings
Exhibit 86: Hikma Pharmaceuticals Plc - Key customers
Exhibit 87: Laboratorios Farmaceuticos Rovi SA - Vendor overview
Exhibit 88: Laboratorios Farmaceuticos Rovi SA - Business segments
Exhibit 89: Laboratorios Farmaceuticos Rovi SA - Organizational developments
Exhibit 90: Laboratorios Farmaceuticos Rovi SA - Segment focus
Exhibit 91: Laboratorios Farmaceuticos Rovi SA - Key offerings
Exhibit 92: Laboratorios Farmaceuticos Rovi SA - Key customers
Exhibit 93: Mylan NV - Vendor overview
Exhibit 94: Mylan NV - Product segments
Exhibit 95: Mylan NV - Organizational developments
Exhibit 96: Mylan NV - Geographic focus
Exhibit 97: Mylan NV - Segment focus
Exhibit 98: Mylan NV - Key offerings
Exhibit 99: Mylan NV - Key customers
Exhibit 100: Nanjing King-Friend Biochemical Pharmaceutical Co. Ltd. - Vendor overview
Exhibit 101: Nanjing King-Friend Biochemical Pharmaceutical Co. Ltd. - Product segments
Exhibit 102: Nanjing King-Friend Biochemical Pharmaceutical Co. Ltd. - Organizational developments
Exhibit 103: Nanjing King-Friend Biochemical Pharmaceutical Co. Ltd. - Key offerings
Exhibit 104: Nanjing King-Friend Biochemical Pharmaceutical Co. Ltd. - Key customers
Exhibit 105: Pfizer Inc. - Vendor overview
Exhibit 106: Pfizer Inc. - Business segments
Exhibit 107: Pfizer Inc. - Organizational developments
Exhibit 108: Pfizer Inc. - Geographic focus
Exhibit 109: Pfizer Inc. - Segment focus
Exhibit 110: Pfizer Inc. - Key offerings
Exhibit 111: Pfizer Inc. - Key customers
Exhibit 112: Sanofi - Vendor overview
Exhibit 113: Sanofi - Business segments
Exhibit 114: Sanofi - Organizational developments
Exhibit 115: Sanofi - Geographic focus
Exhibit 116: Sanofi - Segment focus
Exhibit 117: Sanofi - Key offerings
Exhibit 118: Sanofi - Key customers
Exhibit 119: Validation techniques employed for market sizing
Exhibit 120: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Baxter International Inc.
  • Eisai Co. Ltd.
  • Fresenius SE & Co. KGaA
  • Hikma Pharmaceuticals Plc
  • Mylan NV
  • Pfizer Inc.
  • MORE
The publisher recognizes the following companies as the key players in the global heparin market : Aspen Pharmacare Holdings Ltd., Baxter International Inc., Eisai Co. Ltd., Fresenius SE & Co. KGaA, Hikma Pharmaceuticals Plc, Laboratorios Farmaceuticos Rovi SA, Mylan NV, Nanjing King-Friend Biochemical Pharmaceutical Co. Ltd., Pfizer Inc. and Sanofi.

Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is the development of drugs to remove heparin after surgery."

According to the report, one of the major drivers for this market is the increasing prevalence of chronic conditions.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Aspen Pharmacare Holdings Ltd.
  • Baxter International Inc.
  • Eisai Co. Ltd.
  • Fresenius SE & Co. KGaA
  • Hikma Pharmaceuticals Plc
  • Laboratorios Farmaceuticos Rovi SA
  • Mylan NV
  • Nanjing King-Friend Biochemical Pharmaceutical Co. Ltd.
  • Pfizer Inc.
  • Sanofi.
Note: Product cover images may vary from those shown
Adroll
adroll